· PC
· PK
· PD
Enantiomers |
R-metoprolol S-metoprolol |
Presentation |
IV solution Tablets as tartrate (quick) or succinate (slow) |
Administration |
· IV: 1-2mg q2 mins, max 10mg |
Time course |
· Onset 1-2 mins · Duration 5-8 hours |
Absorption |
· Oral bioav 50% single dose, 70% if repeated (?) |
Distribution |
· Plasma protein binding 10% · Moderate lipid solubility · Crosses blood-brain barrier |
Metabolism |
· CYP2D6 O-demethylation > CYP3A4 α-hydroxylation · t1/2β 3-7 hours |
Excretion |
· Metabolites -> urine |
Generation |
· 2nd |
Receptor activity |
· β adrenoceptor antagonist · Fairly β1 selective · No intrinsic sympathomimetic activity (ISA) · Weak membrane stabilizing activity (MSA) |
Receptor activation |
· Gs G protein coupled receptor · ↓cAMP -> ↓PKA activation -> ↓phosphorylation of intracellular targets |
Cardiac pacemaker cells |
· ↓HCN channel activation -> ↓slope phase 4 -> ↓HR |
Ventricular myocyte |
· ↓Phosphorylation of: o Membrane L-Ca2+ and SR Ryanodine-sensitive Ca2+ channel (↓Ca2+ influx) o Myosin (↓rate at which cross-bridge cycling can occur) o Troponin I and phospholamban (↓rate of relaxation) |
CVS effects |
· ↓HR, ↓atrial tachyarrhythmias, ↓AV node conduction · ↓contractility, ↓remodelling in LV failure · ↓cardiac output, ↓mAP acutely (offset by ↑SVR) · +/- Worsen peripheral vascular disease (more a problem if non-selective) · +/- rebound effects if abrupt cessation |
Resp effects |
· Risk bronchospasm (some β2 antagonism) |
CNS effects |
· ↓tremor, depression, fatigue, insomnia, sexual dysfunction, migraine prophylaxis |
Metabolic effects |
· ↑Risk diabetes, ↓autonomic response to ↓BSL, ↓symptoms of ↓BSL (tremor, ↑HR) |
Renal effects |
· ↓Renin release -> ↓Na+/H2O retention -> ↓mAP long term |
Other |
· Hair loss |
Caution if |
· Severe LV failure · Atrioventricular conduction delay · Asthma, COPD · Diabetes |
MSA toxicity |
As for local anaesthetic systemic toxicity: · CNS: excitation (seizures) then depression (coma) · CVS: hypotension, arrhythmia, death |
Feedback welcome at ketaminenightmares@gmail.com